Free Trial

Theravance Biopharma (TBPH) Financials

Theravance Biopharma logo
$11.01 -0.11 (-0.99%)
As of 02:33 PM Eastern
Annual Income Statements for Theravance Biopharma

Annual Income Statements for Theravance Biopharma

This table shows Theravance Biopharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Income / (Loss) Attributable to Common Shareholders
-56 -55 872
Consolidated Net Income / (Loss)
-56 -55 872
Net Income / (Loss) Continuing Operations
-56 -55 -93
Total Pre-Tax Income
-45 -49 -93
Total Operating Income
-47 -56 -92
Total Gross Profit
64 57 51
Total Revenue
64 57 51
Operating Revenue
64 57 51
Total Cost of Revenue
0.00 0.00 0.00
Total Operating Expenses
111 113 143
Selling, General & Admin Expense
69 70 67
Research & Development Expense
38 41 63
Impairment Charge
4.51 0.00 -
Restructuring Charge
0.00 2.74 13
Total Other Income / (Expense), net
2.34 6.77 -0.86
Interest Expense
2.55 2.35 9.40
Other Income / (Expense), net
4.88 9.12 8.55
Income Tax Expense
12 5.92 0.01
Basic Earnings per Share
($1.15) ($1.00) $11.85
Weighted Average Basic Shares Outstanding
48.85M 55.30M 73.59M
Diluted Earnings per Share
($1.15) ($1.00) $11.85
Weighted Average Diluted Shares Outstanding
48.85M 55.30M 73.59M
Weighted Average Basic & Diluted Shares Outstanding
49.47M 48.16M 62.86M

Quarterly Income Statements for Theravance Biopharma

This table shows Theravance Biopharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders
-16 -13 -17 -12 -8.51 -8.95 -16 -22 -10 917
Consolidated Net Income / (Loss)
-16 -13 -17 -12 -8.51 -8.95 -16 -22 -10 917
Net Income / (Loss) Continuing Operations
-16 -13 -17 -12 -8.51 -8.95 -16 -22 -14 -16
Total Pre-Tax Income
-8.94 -10 -15 -10 -5.02 -7.58 -14 -22 -14 -16
Total Operating Income
-9.20 -11 -16 -11 -6.24 -8.76 -16 -25 -17 -14
Total Gross Profit
19 17 14 15 18 16 14 10 15 12
Total Revenue
19 17 14 15 18 16 14 10 15 12
Operating Revenue
19 17 14 15 18 16 14 10 15 12
Total Operating Expenses
28 28 30 26 24 24 30 35 32 27
Selling, General & Admin Expense
19 17 17 17 15 16 19 19 17 16
Research & Development Expense
9.45 9.27 9.95 8.97 8.31 8.31 9.43 15 15 9.87
Total Other Income / (Expense), net
0.26 0.79 0.48 0.81 1.22 1.18 1.94 2.43 3.17 -1.82
Interest Expense
0.64 0.63 0.64 0.63 0.62 0.61 0.57 0.55 0.55 4.58
Other Income / (Expense), net
0.90 1.42 1.13 1.43 1.85 1.79 2.50 2.98 3.72 2.76
Income Tax Expense
6.59 2.65 1.31 1.26 3.49 1.37 1.46 -0.40 -0.51 0.00
Basic Earnings per Share
($0.31) ($0.26) ($0.34) ($0.24) ($0.20) ($0.17) ($0.28) ($0.35) $0.16 $12.14
Weighted Average Basic Shares Outstanding
48.85M 49.04M 48.75M 48.28M 55.30M 52.36M 56.68M 62.93M 73.59M 75.52M
Diluted Earnings per Share
($0.31) ($0.26) ($0.34) ($0.24) ($0.20) ($0.17) ($0.28) ($0.35) $0.16 $12.14
Weighted Average Diluted Shares Outstanding
48.85M 49.04M 48.75M 48.28M 55.30M 52.36M 56.68M 62.93M 73.59M 75.52M
Weighted Average Basic & Diluted Shares Outstanding
49.47M 49.17M 48.92M 48.63M 48.16M 49.80M 52.81M 57.80M 62.86M 67.37M

Annual Cash Flow Statements for Theravance Biopharma

This table details how cash moves in and out of Theravance Biopharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Change in Cash & Equivalents
-1.75 -259 208
Net Cash From Operating Activities
-12 -27 -187
Net Cash From Continuing Operating Activities
-12 -27 -2.43
Net Income / (Loss) Continuing Operations
-56 -55 -93
Consolidated Net Income / (Loss)
-56 -55 872
Depreciation Expense
1.71 2.00 3.72
Amortization Expense
1.91 2.26 3.99
Non-Cash Adjustments To Reconcile Net Income
29 25 42
Changes in Operating Assets and Liabilities, net
12 -0.60 41
Net Cash From Investing Activities
12 -33 1,154
Net Cash From Continuing Investing Activities
12 -33 59
Purchase of Property, Plant & Equipment
-0.33 -2.49 -0.57
Purchase of Investments
-141 -135 -103
Sale of Property, Plant & Equipment
0.00 1.51 1.87
Sale and/or Maturity of Investments
156 103 158
Other Investing Activities, net
-2.29 0.00 -
Net Cash From Financing Activities
-2.50 -199 -759
Net Cash From Continuing Financing Activities
-2.50 -199 -739
Repurchase of Common Equity
-0.45 -197 -129
Issuance of Common Equity
0.61 0.62 0.80
Other Financing Activities, net
-2.66 -2.50 21
Cash Income Taxes Paid
0.11 0.02 118

Quarterly Cash Flow Statements for Theravance Biopharma

This table details how cash moves in and out of Theravance Biopharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents
14 -23 -7.49 14 -32 -34 -82 -111 -120 331
Net Cash From Operating Activities
-0.90 -5.20 -4.42 -1.02 -0.85 -2.49 -12 -11 -124 -22
Net Cash From Continuing Operating Activities
-0.90 -5.20 -5.44 0.00 -0.85 -2.49 -24 0.00 55 -17
Net Income / (Loss) Continuing Operations
-16 -13 -17 -12 -8.51 -8.95 -16 -22 -14 -16
Consolidated Net Income / (Loss)
-16 -13 -17 -12 -8.51 -8.95 -16 -22 -10 917
Depreciation Expense
0.42 0.43 0.43 0.43 0.39 0.43 0.55 0.63 0.66 1.11
Amortization Expense
0.27 0.33 0.55 0.75 1.03 0.51 0.37 0.35 1.71 0.97
Non-Cash Adjustments To Reconcile Net Income
10 4.73 7.20 7.19 3.81 3.60 6.11 11 3.87 9.88
Changes in Operating Assets and Liabilities, net
3.60 2.01 3.94 2.28 2.43 1.93 -3.82 -1.14 63 -13
Net Cash From Investing Activities
16 -17 -3.03 17 -0.68 -0.02 11 -43 39 1,075
Net Cash From Continuing Investing Activities
16 -17 14 0.00 -0.68 -0.02 -32 0.00 39 -20
Purchase of Property, Plant & Equipment
-0.19 -0.02 -0.04 -0.09 -0.68 -0.02 -0.85 -0.94 -0.27 0.06
Purchase of Investments
-38 -45 -31 -27 - - -0.00 -135 -9.89 -39
Sale and/or Maturity of Investments
56 27 28 44 - - 11 92 49 17
Net Cash From Financing Activities
-0.37 -0.37 -0.04 -1.72 -31 -31 -81 -56 -35 -722
Net Cash From Continuing Financing Activities
-0.37 -0.37 -1.76 0.00 -31 -31 -137 0.00 -35 -702
Issuance of Common Equity
0.16 0.03 - - 0.17 -0.00 - - 0.31 0.00
Other Financing Activities, net
-0.53 -0.40 -0.46 -1.27 -0.52 -0.51 -0.58 -0.89 -0.99 24
Cash Income Taxes Paid
0.10 - 0.02 -0.01 0.01 - 0.01 0.01 118 0.00

Annual Balance Sheets for Theravance Biopharma

This table presents Theravance Biopharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Total Assets
354 382 607
Total Current Assets
161 134 353
Cash & Equivalents
38 40 298
Short-Term Investments
51 63 29
Prepaid Expenses
4.28 14 9.20
Other Current Assets
68 17 17
Plant, Property, & Equipment, net
7.42 9.07 12
Total Noncurrent Assets
186 239 242
Other Noncurrent Operating Assets
186 239 242
Total Liabilities & Shareholders' Equity
354 382 607
Total Liabilities
179 169 166
Total Current Liabilities
32 25 29
Accounts Payable
2.24 1.52 1.55
Accrued Expenses
6.26 6.39 10
Current Deferred & Payable Income Tax Liabilities
5.85 0.00 -
Current Employee Benefit Liabilities
7.02 6.44 10
Other Current Liabilities
11 10 6.75
Total Noncurrent Liabilities
147 144 137
Noncurrent Deferred & Payable Income Tax Liabilities
75 65 64
Other Noncurrent Operating Liabilities
71 79 73
Commitments & Contingencies
0.00 0.00 0.00
Total Equity & Noncontrolling Interests
176 213 442
Total Preferred & Common Equity
176 213 442
Preferred Stock
0.00 0.00 0.00
Total Common Equity
176 213 442
Common Stock
1,141 1,122 1,296
Retained Earnings
-966 -909 -854
Accumulated Other Comprehensive Income / (Loss)
0.01 -0.07 -0.02

Quarterly Balance Sheets for Theravance Biopharma

This table presents Theravance Biopharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets
356 362 371 414 447 539 763
Total Current Assets
116 119 124 162 192 261 512
Cash & Equivalents
23 46 54 72 106 188 419
Short-Term Investments
68 50 46 62 62 54 68
Prepaid Expenses
8.27 8.93 9.66 11 8.76 7.81 11
Other Current Assets
17 14 15 17 16 12 14
Plant, Property, & Equipment, net
7.79 8.14 8.72 9.29 9.55 12 12
Total Noncurrent Assets
232 235 238 243 245 265 240
Other Noncurrent Operating Assets
232 235 238 243 245 246 240
Total Liabilities & Shareholders' Equity
356 362 371 414 447 539 763
Total Liabilities
170 168 166 167 166 168 283
Total Current Liabilities
23 23 22 25 25 26 142
Accounts Payable
1.45 1.67 1.69 2.37 1.57 2.66 5.34
Accrued Expenses
3.45 4.79 4.95 6.69 8.42 11 7.97
Current Employee Benefit Liabilities
7.84 5.77 4.48 6.58 5.37 5.03 7.56
Other Current Liabilities
11 11 11 9.71 9.16 7.43 0.69
Total Noncurrent Liabilities
147 145 145 142 142 142 141
Noncurrent Deferred & Payable Income Tax Liabilities
72 69 67 66 65 64 63
Other Noncurrent Operating Liabilities
75 76 78 76 77 77 78
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
186 194 205 246 280 371 481
Total Preferred & Common Equity
186 194 205 246 280 371 481
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
186 194 205 246 280 371 481
Common Stock
1,136 1,131 1,126 1,147 1,172 1,247 1,324
Retained Earnings
-950 -937 -921 -901 -892 -876 -844
Accumulated Other Comprehensive Income / (Loss)
0.05 -0.02 -0.04 -0.23 -0.29 0.05 -0.12

Annual Metrics And Ratios for Theravance Biopharma

This table displays calculated financial ratios and metrics derived from Theravance Biopharma's official financial filings.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Growth Metrics
- - -
Revenue Growth
12.12% 11.84% -7.17%
EBITDA Growth
9.87% 43.65% 69.48%
EBIT Growth
10.34% 43.75% 67.50%
NOPAT Growth
16.21% 39.06% 64.33%
Net Income Growth
-2.22% -106.33% 537.32%
EPS Growth
-15.00% -108.44% 512.89%
Operating Cash Flow Growth
57.27% 85.56% 10.04%
Free Cash Flow Firm Growth
73.25% 92.02% -62.34%
Invested Capital Growth
-21.14% -3.28% 143.01%
Revenue Q/Q Growth
1.88% 5.35% -0.58%
EBITDA Q/Q Growth
-20.43% 16.40% 36.33%
EBIT Q/Q Growth
-10.23% 16.57% 33.55%
NOPAT Q/Q Growth
-6.73% 16.65% 29.64%
Net Income Q/Q Growth
-14.20% 3.25% 2.55%
EPS Q/Q Growth
-10.58% -56.25% 4.50%
Operating Cash Flow Q/Q Growth
-0.42% 82.03% -77.46%
Free Cash Flow Firm Q/Q Growth
26.76% 78.56% -4.83%
Invested Capital Q/Q Growth
-7.53% -1.39% 1,927.89%
Profitability Metrics
- - -
Gross Margin
100.00% 100.00% 100.00%
EBITDA Margin
-59.73% -74.29% -147.44%
Operating Margin
-72.92% -97.58% -179.09%
EBIT Margin
-65.34% -81.71% -162.45%
Profit (Net Income) Margin
-87.63% -96.11% 1,698.54%
Tax Burden Percent
126.46% 112.02% -939.65%
Interest Burden Percent
106.05% 105.01% 111.27%
Effective Tax Rate
0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-33.24% -34.88% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
-8.54% -27.46% 0.00%
Return on Net Nonoperating Assets (RNNOA)
4.19% 18.03% 0.00%
Return on Equity (ROE)
-29.04% -16.86% 1,689.74%
Cash Return on Invested Capital (CROIC)
-9.60% -31.55% -388.84%
Operating Return on Assets (OROA)
-11.43% -9.48% -16.98%
Return on Assets (ROA)
-15.33% -11.16% 177.58%
Return on Common Equity (ROCE)
-29.04% -16.86% 1,689.74%
Return on Equity Simple (ROE_SIMPLE)
-32.14% -25.91% 197.40%
Net Operating Profit after Tax (NOPAT)
-33 -39 -64
NOPAT Margin
-51.05% -68.31% -125.37%
Net Nonoperating Expense Percent (NNEP)
-24.69% -7.43% 735.30%
Return On Investment Capital (ROIC_SIMPLE)
-18.72% -18.42% -
Cost of Revenue to Revenue
0.00% 0.00% 0.00%
SG&A Expenses to Revenue
107.44% 122.07% 130.63%
R&D to Revenue
58.47% 70.74% 123.46%
Operating Expenses to Revenue
172.92% 197.58% 279.09%
Earnings before Interest and Taxes (EBIT)
-42 -47 -83
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-38 -43 -76
Valuation Ratios
- - -
Price to Book Value (P/BV)
2.64 2.63 1.71
Price to Tangible Book Value (P/TBV)
2.64 2.63 1.71
Price to Revenue (P/Rev)
7.19 9.75 14.72
Price to Earnings (P/E)
0.00 0.00 0.87
Dividend Yield
0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 115.39%
Enterprise Value to Invested Capital (EV/IC)
4.29 4.14 3.75
Enterprise Value to Revenue (EV/Rev)
5.82 7.96 8.34
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00
Leverage & Solvency
- - -
Debt to Equity
0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00
Financial Leverage
-0.49 -0.66 -2.47
Leverage Ratio
1.89 1.51 9.52
Compound Leverage Factor
2.01 1.59 10.59
Debt to Total Capital
0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00
Altman Z-Score
-2.04 -1.26 1.04
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00%
Liquidity Ratios
- - -
Current Ratio
5.02 5.39 12.31
Quick Ratio
2.75 4.14 11.40
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
-9.49 -35 -445
Operating Cash Flow to CapEx
-3,474.40% -2,768.92% 0.00%
Free Cash Flow to Firm to Interest Expense
-3.73 -15.10 -47.27
Operating Cash Flow to Interest Expense
-4.53 -11.49 -19.89
Operating Cash Flow Less CapEx to Interest Expense
-4.66 -11.90 -19.75
Efficiency Ratios
- - -
Asset Turnover
0.17 0.12 0.10
Accounts Receivable Turnover
0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00
Fixed Asset Turnover
7.81 5.48 4.02
Accounts Payable Turnover
0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00
Capital & Investment Metrics
- - -
Invested Capital
87 111 114
Invested Capital Turnover
0.65 0.51 -0.68
Increase / (Decrease) in Invested Capital
-23 -3.75 380
Enterprise Value (EV)
374 457 428
Market Capitalization
463 560 756
Book Value per Share
$3.57 $4.28 $6.56
Tangible Book Value per Share
$3.57 $4.28 $6.56
Total Capital
176 213 442
Total Debt
0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00
Net Debt
-88 -102 -327
Capital Expenditures (CapEx)
0.33 0.98 -1.29
Debt-free, Cash-free Net Working Capital (DFCFNWC)
41 6.35 -2.74
Debt-free Net Working Capital (DFNWC)
129 109 325
Net Working Capital (NWC)
129 109 325
Net Nonoperating Expense (NNE)
24 16 -937
Net Nonoperating Obligations (NNO)
-88 -102 -327
Total Depreciation and Amortization (D&A)
3.62 4.26 7.71
Debt-free, Cash-free Net Working Capital to Revenue
63.11% 11.05% -5.33%
Debt-free Net Working Capital to Revenue
200.34% 189.42% 632.47%
Net Working Capital to Revenue
200.34% 189.42% 632.47%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
($1.15) ($1.00) $11.85
Adjusted Weighted Average Basic Shares Outstanding
48.85M 55.30M 73.59M
Adjusted Diluted Earnings per Share
($1.15) ($1.00) $11.85
Adjusted Weighted Average Diluted Shares Outstanding
48.85M 55.30M 73.59M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
49.47M 48.16M 62.86M
Normalized Net Operating Profit after Tax (NOPAT)
-30 -37 -55
Normalized NOPAT Margin
-46.14% -64.96% -107.86%
Pre Tax Income Margin
-69.30% -85.80% -180.76%
Debt Service Ratios
- - -
EBIT to Interest Expense
-16.52 -19.97 -8.87
NOPAT to Interest Expense
-12.91 -16.69 -6.85
EBIT Less CapEx to Interest Expense
-16.65 -20.38 -8.73
NOPAT Less CapEx to Interest Expense
-13.04 -17.11 -6.71
Payout Ratios
- - -
Dividend Payout Ratio
0.00% 0.00% 0.00%
Augmented Payout Ratio
-0.79% -357.02% 14.77%

Quarterly Metrics And Ratios for Theravance Biopharma

This table displays calculated financial ratios and metrics derived from Theravance Biopharma's official financial filings.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics
- - - - - - - - - -
Revenue Growth
6.77% 7.49% 3.69% 39.22% 19.91% 26.04% 24.43% -21.06% -1.99% -5.63%
EBITDA Growth
-155.41% -43.45% -7.11% 58.99% 73.77% 35.54% 32.18% 42.24% 79.20% 81.70%
EBIT Growth
-88.85% -35.10% -7.03% 55.44% 67.96% 39.06% 34.08% 41.66% 75.44% 78.72%
NOPAT Growth
-47.44% -23.71% 2.59% 55.01% 64.20% 38.32% 30.21% 33.07% 68.97% 73.51%
Net Income Growth
-82.46% -41.88% -5.65% 47.19% 17.87% -100.98% -91.00% 14.87% 67.65% 2,696.10%
EPS Growth
-55.00% -52.94% -21.43% 31.43% -225.00% -101.40% -154.55% -2.94% 145.71% 2,629.17%
Operating Cash Flow Growth
-5.62% -109.01% 64.50% 90.89% 99.31% 88.77% 15.57% 56.96% -192.35% 51.29%
Free Cash Flow Firm Growth
2,826.89% 108.23% 100.79% 99.54% 99.84% 63.64% -2,796.90% -1,302.63% -195.72% -297.57%
Invested Capital Growth
-21.14% -15.91% -13.40% -5.09% -3.28% 1,892.88% 128.29% 131.58% 143.01% 98.15%
Revenue Q/Q Growth
11.18% 18.32% -1.70% -17.43% 11.93% 14.14% 31.99% -28.89% 17.65% 12.68%
EBITDA Q/Q Growth
12.23% 36.31% -58.23% -234.01% 50.70% 52.45% 39.42% -84.71% -21.13% 49.97%
EBIT Q/Q Growth
11.95% 35.36% -49.16% -122.47% 37.01% 48.79% 37.91% -59.99% -19.79% 44.61%
NOPAT Q/Q Growth
15.11% 31.00% -40.14% -79.60% 28.77% 45.67% 35.28% -42.92% -22.74% 38.52%
Net Income Q/Q Growth
-22.28% 23.18% -41.71% -37.06% 4.92% 42.79% 29.17% -113.16% -101.13% 11,290.71%
EPS Q/Q Growth
-19.23% 23.53% -41.67% -20.00% -17.65% 39.29% 20.00% -318.75% -98.68% 11,136.36%
Operating Cash Flow Q/Q Growth
82.64% -17.69% -332.00% -19.67% 65.65% 80.01% -10.83% 90.95% -460.40% -50.29%
Free Cash Flow Firm Q/Q Growth
65.24% 149.62% 285.11% -257.15% 99.50% 76.16% -9.31% -21.80% -14.56% -1,868.22%
Invested Capital Q/Q Growth
-7.53% -3.40% -6.94% -5.13% -1.39% -0.52% 1.98% -3.32% 1,927.89% 98.43%
Profitability Metrics
- - - - - - - - - -
Gross Margin
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin
-40.53% -51.34% -95.38% -59.26% -16.94% -38.47% -92.33% -201.16% -77.45% -75.22%
Operating Margin
-49.06% -64.25% -110.16% -77.27% -35.53% -55.82% -117.27% -239.15% -118.99% -114.06%
EBIT Margin
-44.24% -55.86% -102.25% -67.39% -25.01% -44.44% -99.05% -210.55% -93.58% -91.91%
Profit (Net Income) Margin
-82.79% -75.28% -115.94% -80.42% -48.45% -57.03% -113.79% -212.04% -70.74% 7,361.91%
Tax Burden Percent
173.70% 126.32% 108.59% 112.13% 169.66% 118.03% 110.28% 98.24% 72.67% -5,720.72%
Interest Burden Percent
107.75% 106.69% 104.42% 106.44% 114.18% 108.73% 104.17% 102.51% 104.01% 140.01%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-22.36% -27.53% -45.48% -30.89% -12.70% -40.23% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
-12.83% -23.00% -41.28% -28.77% -10.77% -39.33% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
6.30% 12.00% 22.96% 18.00% 7.07% 33.60% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-16.06% -15.53% -22.52% -12.89% -5.63% -6.64% -2,494.07% 9,168.35% 1,689.74% 1,083.49%
Cash Return on Invested Capital (CROIC)
-9.60% -12.56% -13.54% -22.29% -31.55% -147.55% -498.56% -467.06% -388.84% 0.00%
Operating Return on Assets (OROA)
-7.74% -9.17% -15.68% -9.11% -2.90% -4.12% -12.58% -22.88% -9.78% -8.14%
Return on Assets (ROA)
-14.48% -12.36% -17.78% -10.87% -5.62% -5.28% -14.45% -23.04% -7.40% 651.79%
Return on Common Equity (ROCE)
-16.06% -15.53% -22.52% -12.89% -5.63% -6.64% -2,494.07% 9,168.35% 1,689.74% 1,083.49%
Return on Equity Simple (ROE_SIMPLE)
0.00% -26.61% -23.57% -21.85% 0.00% -23.18% 310.01% 236.40% 0.00% 176.97%
Net Operating Profit after Tax (NOPAT)
-6.44 -7.59 -11 -7.84 -4.37 -6.13 -11 -17 -12 -9.94
NOPAT Margin
-34.34% -44.97% -77.11% -54.09% -24.87% -39.07% -82.09% -167.40% -83.29% -79.84%
Net Nonoperating Expense Percent (NNEP)
-9.53% -4.54% -4.20% -2.12% -1.93% -0.91% -4.04% -3.60% 1.44% 369.13%
Return On Investment Capital (ROIC_SIMPLE)
-3.67% - - - -2.05% - - - - -
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
98.65% 100.04% 119.64% 115.44% 88.20% 102.86% 140.21% 184.15% 114.22% 130.73%
R&D to Revenue
50.41% 54.94% 69.82% 61.84% 47.33% 52.96% 68.55% 139.89% 104.77% 79.25%
Operating Expenses to Revenue
149.06% 164.25% 210.16% 177.27% 135.53% 155.82% 217.27% 339.15% 218.99% 214.06%
Earnings before Interest and Taxes (EBIT)
-8.30 -9.42 -15 -9.77 -4.39 -6.97 -14 -22 -14 -11
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-7.60 -8.66 -14 -8.59 -2.98 -6.04 -13 -21 -11 -9.37
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
2.64 2.12 2.13 2.11 2.63 1.85 2.14 1.84 1.71 1.61
Price to Tangible Book Value (P/TBV)
2.64 2.12 2.13 2.11 2.63 1.85 2.14 1.84 1.71 1.61
Price to Revenue (P/Rev)
7.19 6.24 6.65 7.02 9.75 8.36 11.67 14.04 14.72 15.01
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.69 0.78 0.87 0.91
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 145.19% 128.43% 115.39% 109.74%
Enterprise Value to Invested Capital (EV/IC)
4.29 3.21 3.24 3.17 4.14 2.87 3.82 3.82 3.75 0.00
Enterprise Value to Revenue (EV/Rev)
5.82 4.79 5.10 5.40 7.96 5.90 8.40 8.69 8.34 5.58
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-0.49 -0.52 -0.56 -0.63 -0.66 -0.85 3.10 -13.53 -2.47 -3.20
Leverage Ratio
1.89 1.78 1.71 1.58 1.51 1.62 -11.59 46.78 9.52 7.43
Compound Leverage Factor
2.04 1.90 1.78 1.68 1.73 1.76 -12.08 47.95 9.90 10.40
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
-1.72 -1.94 -1.80 -1.50 -0.89 -0.94 -0.17 0.64 1.42 0.70
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
5.02 4.97 5.20 5.74 5.39 6.37 7.82 9.98 12.31 3.60
Quick Ratio
2.75 3.90 4.19 4.62 4.14 5.28 6.82 9.21 11.40 3.43
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
17 10 4.11 -2.22 -0.62 -125 -522 -478 -392 -342
Operating Cash Flow to CapEx
-474.74% -34,640.00% -12,263.89% -1,123.08% -126.14% -11,838.10% 0.00% -1,541.35% -46,637.22% 0.00%
Free Cash Flow to Firm to Interest Expense
26.34 16.27 6.38 -3.53 -1.00 -204.45 -919.62 -868.87 -713.34 -74.79
Operating Cash Flow to Interest Expense
-1.40 -8.25 -6.86 -1.62 -1.37 -4.08 -21.89 -20.40 -225.55 -4.83
Operating Cash Flow Less CapEx to Interest Expense
-1.70 -8.27 -6.91 -1.77 -2.46 -4.12 -21.10 -21.73 -226.04 -4.82
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.17 0.16 0.15 0.14 0.12 0.09 0.13 0.11 0.10 0.09
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
7.81 7.40 7.01 5.91 5.48 5.15 4.64 3.83 4.02 3.70
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
87 94 98 105 111 112 113 111 114 -6.25
Invested Capital Turnover
0.65 0.61 0.59 0.57 0.51 1.03 -0.36 -0.41 -0.68 -0.30
Increase / (Decrease) in Invested Capital
-23 -18 -15 -5.63 -3.75 118 511 460 380 333
Enterprise Value (EV)
374 303 316 332 457 322 431 422 428 288
Market Capitalization
463 394 412 432 560 456 598 682 756 775
Book Value per Share
$3.57 $3.79 $3.98 $4.25 $4.28 $4.66 $4.94 $5.89 $6.56 $6.29
Tangible Book Value per Share
$3.57 $3.79 $3.98 $4.25 $4.28 $4.66 $4.94 $5.89 $6.56 $6.29
Total Capital
176 186 194 205 213 246 280 371 442 481
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-88 -91 -96 -100 -102 -134 -167 -260 -327 -487
Capital Expenditures (CapEx)
0.19 0.02 0.04 0.09 0.68 0.02 -0.45 0.73 0.27 -0.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)
41 1.68 0.28 2.66 6.35 2.32 0.01 -6.11 -2.74 -117
Debt-free Net Working Capital (DFNWC)
129 93 96 103 109 136 167 235 325 370
Net Working Capital (NWC)
129 93 96 103 109 136 167 235 325 370
Net Nonoperating Expense (NNE)
9.09 5.11 5.54 3.82 4.14 2.82 4.36 4.65 -1.84 -927
Net Nonoperating Obligations (NNO)
-88 -91 -96 -100 -102 -134 -167 -260 -327 -487
Total Depreciation and Amortization (D&A)
0.70 0.76 0.98 1.18 1.42 0.94 0.92 0.98 2.36 2.08
Debt-free, Cash-free Net Working Capital to Revenue
63.11% 2.66% 0.46% 4.32% 11.05% 4.25% 0.01% -12.58% -5.33% -227.03%
Debt-free Net Working Capital to Revenue
200.34% 147.24% 155.38% 166.85% 189.42% 250.10% 326.64% 484.18% 632.47% 715.66%
Net Working Capital to Revenue
200.34% 147.24% 155.38% 166.85% 189.42% 250.10% 326.64% 484.18% 632.47% 715.66%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($0.31) ($0.26) ($0.34) ($0.24) ($0.20) ($0.17) ($0.28) ($0.35) $0.16 $12.14
Adjusted Weighted Average Basic Shares Outstanding
48.85M 49.04M 48.75M 48.28M 55.30M 52.36M 56.68M 62.93M 73.59M 75.52M
Adjusted Diluted Earnings per Share
($0.31) ($0.26) ($0.34) ($0.24) ($0.20) ($0.17) ($0.28) ($0.35) $0.16 $12.14
Adjusted Weighted Average Diluted Shares Outstanding
48.85M 49.04M 48.75M 48.28M 55.30M 52.36M 56.68M 62.93M 73.59M 75.52M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
49.47M 49.17M 48.92M 48.63M 48.16M 49.80M 52.81M 57.80M 62.86M 67.37M
Normalized Net Operating Profit after Tax (NOPAT)
-6.44 -6.49 -8.93 -7.84 -4.37 -6.13 -10 -16 -12 -9.59
Normalized NOPAT Margin
-34.34% -38.49% -62.62% -54.09% -24.87% -39.07% -76.14% -156.83% -83.29% -76.98%
Pre Tax Income Margin
-47.66% -59.59% -106.77% -71.72% -28.56% -48.32% -103.19% -215.83% -97.34% -128.69%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
-12.90 -14.96 -22.64 -15.54 -7.05 -11.45 -23.98 -39.88 -24.93 -2.50
NOPAT to Interest Expense
-10.02 -12.04 -17.07 -12.47 -7.01 -10.07 -19.87 -31.71 -22.18 -2.17
EBIT Less CapEx to Interest Expense
-13.20 -14.98 -22.69 -15.68 -8.14 -11.49 -23.18 -41.20 -25.41 -2.49
NOPAT Less CapEx to Interest Expense
-10.31 -12.06 -17.13 -12.62 -8.10 -10.10 -19.08 -33.03 -22.67 -2.16
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
-0.79% -62.16% -134.93% -317.50% -357.02% -353.37% 30.48% 21.03% 14.77% 11.06%

Frequently Asked Questions About Theravance Biopharma's Financials

When does Theravance Biopharma's financial year end?

According to the most recent income statement we have on file, Theravance Biopharma's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Theravance Biopharma's net income changed over the last 2 years?

Theravance Biopharma's net income appears to be on a downward trend, with a most recent value of -$56.42 million in 2024, falling from $872.13 million in 2022. The previous period was -$55.19 million in 2023. See where experts think Theravance Biopharma is headed by visiting Theravance Biopharma's forecast page.

What is Theravance Biopharma's operating income?
Theravance Biopharma's total operating income in 2024 was -$46.95 million, based on the following breakdown:
  • Total Gross Profit: $64.38 million
  • Total Operating Expenses: $111.33 million
How has Theravance Biopharma revenue changed over the last 2 years?

Over the last 2 years, Theravance Biopharma's total revenue changed from $51.35 million in 2022 to $64.38 million in 2024, a change of 25.4%.

How much debt does Theravance Biopharma have?

Theravance Biopharma's total liabilities were at $178.62 million at the end of 2024, a 5.7% increase from 2023, and a 7.9% increase since 2022.

How much cash does Theravance Biopharma have?

In the past 2 years, Theravance Biopharma's cash and equivalents has ranged from $37.80 million in 2024 to $298.17 million in 2022, and is currently $37.80 million as of their latest financial filing in 2024.

How has Theravance Biopharma's book value per share changed over the last 2 years?

Over the last 2 years, Theravance Biopharma's book value per share changed from 6.56 in 2022 to 3.57 in 2024, a change of -45.6%.



This page (NASDAQ:TBPH) was last updated on 6/4/2025 by MarketBeat.com Staff
From Our Partners